Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,856 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 6,856 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
G1 Therapeutics, Inc.
Report date September 18, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-09-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-18 · Disposition to issuer · Disposed 10,000 · Balance 10,000 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2: (Continued form footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Row 2 · 2024-09-18 · Other · Disposed 10,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2032-06-27 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-09-18 · Disposition to issuer · Disposed 60,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration").
F2: (Continued form footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 11,389 | $0.00 Strike: $49.56 | $0.00 |
DisclosureSEC source: 0001935943-26-000002 · wk-form4_1781641121.xml · derivative · entry 2 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Stock · 11,389 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001935943-26-000002 · wk-form4_1781641121.xml · nonDerivative · entry 1 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,856 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,372 | $0.00 Strike: $34.46 | $0.00 |
DisclosureSEC source: 0001935943-25-000004 · wk-form4_1750111630.xml · derivative · entry 2 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,372 Underlying: Common Stock · 15,372 shares Expires 2035-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001935943-25-000004 · wk-form4_1750111630.xml · nonDerivative · entry 1 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,591 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $5.35 | Not disclosed |
DisclosureSEC source: 0000950170-24-107793 · ownership.xml · derivative · entry 5 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2032-06-27 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.83 | Not disclosed |
DisclosureSEC source: 0000950170-24-107793 · ownership.xml · derivative · entry 4 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2033-06-15 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.99 | Not disclosed |
DisclosureSEC source: 0000950170-24-107793 · ownership.xml · derivative · entry 3 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2034-06-13 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | OtherCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107793 · ownership.xml · nonDerivative · entry 2 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107793 · ownership.xml · nonDerivative · entry 1 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2 · kind: (Continued form footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2 · price: (Continued form footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:40 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001562180-24-005080 · primarydocument.xml · derivative · entry 2 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-13 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:40 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005080 · primarydocument.xml · nonDerivative · entry 1 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 10,000 RSUs from award granted on June 15, 2023; and (ii) 10,000 RSUs from award granted on June 13, 2024. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001649094-24-000015 · wk-form4_1718050330.xml · derivative · entry 2 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000015 · wk-form4_1718050330.xml · nonDerivative · entry 1 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 21:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001209191-23-056913 · doc4.xml · derivative · entry 1 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-11-26 F1 · derivative.exercise_date: Option shall vest over 36 months, 1/3 of which will vest on November 27, 2024 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:06 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001562180-23-005268 · primarydocument.xml · derivative · entry 2 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-15 F3 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:06 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005268 · primarydocument.xml · nonDerivative · entry 1 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 17:56 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to buy) · Derivative | 60,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001562180-22-005393 · primarydocument.xml · derivative · entry 1 Lee Jacks · CIK 0001935943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: The shares underlying this option vest in 36 equal monthly installments beginning on June 30, 2022, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.